Similar articles

Abstract: Objective: Our objective was to construct a recombinant bacillus Calmette-Gué;rin vaccine (rBCG) that secretes human interferon-alpha 2b (IFNα-2b) and to study its immunogenicity and in vitro antitumor activity against human bladder cancer cell lines T24 and T5637. Methods: The signal sequence BCG Ag85B and the gene IFNα-2b were amplified from the genome of BCG and human peripheral blood, respectively, by polymerase chain reaction (PCR). The two genes were cloned in Escherichia coli-BCG shuttle-vector pMV261 to obtain a new recombinant plasmid pMV261-Ag85B-IFNα-2b. BCG was transformed with the recombinant plasmid by electroporation and designated rBCG-IFNα-2b. Mononuclear cells were isolated from human peripheral blood (PBMCs) and stimulated with rBCG-IFNα-2b or wild type BCG for 3 d, and then cultured with human bladder cancer cell lines T24 and T5637. Their cytotoxicities were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: BCG was successfully transformed with the recombinant plasmid pMV261-Ag85B-IFNα-2b by electroporation and the recombinant BCG (rBCG-IFNα-2b) was capable of synthesizing and secreting cytokine IFNα-2b. PBMC proliferation was enhanced significantly by rBCG-IFNα-2b, and the cytotoxicity of PBMCs stimulated by rBCG-IFNα-2b to T24 and T5627 was significantly stronger in comparison to wild type BCG. Conclusions: A recombinant BCG, secreting human IFNα-2b (rBCG-IFNα-2b), was constructed successfully and was superior to control wild type BCG in inducing immune responses and enhancing cytotoxicity to human bladder cancer cell lines T24 and T5637. This suggests that rBCG-IFNα-2b could be a promising agent for bladder cancer patients in terms of possible reductions in both clinical dosage and side effects of BCG immunotherapy.

[1]Agarwal, A., Agrawal, U., Verma, S., Mohanty, N.K., Saxena, S., 2010. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol. Immunotoxicol., 32(2):348-356.

[2]Alexandroff, A.B., Nicholson, S., Patel, P.M., Jackson, A.M., 2010. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy, 2(4):551-560.

[3]Arnold, J., de Boer, E.C., O′Donnell, M.A., Böhle, A., Brandau, S., 2004. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J. Immunother., 27(2):116-123.

[4]Belldegrun, A.S., Franklin, J.R., O′Donnell, M.A., Gomella, L.G., Klein, E., Neri, R., Nseyo, U.O., Ratliff, T.L., Williams, R.D., 1998. Superficial bladder cancer: the role of interferon-alpha. J. Urol., 159(6):1793-1801.

[5]Bowyer, L., Hall, R.R., Reading, J., Marsh, M.M., 1995. The persistence of bacille Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. Br. J. Urol., 75(2):188-192.

[6]Chade, D.C., Borra, R.C., Nascimento, I.P., Villanova, F.E., Leite, L.C., Andrade, E., Srougi, M., Ramos, K.L., Andrade, P.M., 2008. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J. Exp. Clin. Cancer Res., 27(1):78.

[7]de Boer, E.C., Rooijakkers, S.J., Schamhart, D.H., Kurth, K.H., 2003. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J. Urol., 170(5):2004-2008.

[8]Durek, C., Richter, E., Basteck, A., Rüsch-Gerdes, S., Gerdes, J., Jocham, D., Böhle, A., 2001. The fate of bacillus Calmette-Guerin after intravesical instillation. J. Urol., 165(5):1765-1768.

[9]Gakis, G., Todenhofer, T., Renninger, M., Schilling, D., Sievert, K.D., Schwentner, C., Stenzl, A., 2011. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int., 108(11):1800-1805.

[10]Hassen, W., Droller, M.J., 2000. Current concepts in assessment and treatment of bladder cancer. Curr. Opin. Urol., 10(4):291-299.

[11]Lee, C.F., Chang, S.Y., Hsieh, D.S., Yu, D.S., 2004. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J. Urol., 171(3):1343-1347.

[12]Liu, W., O′Donnell, M.A., Chen, X., Han, R., Luo, Y., 2009. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2b enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol. Immunother., 58(10):1647-1655.

[13]Luo, Y., Szilvasi, A., Chen, X., deWolf, W.C., O′Donnell, M.A., 1996. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin. Diagn Lab. Immunol., 3(6):761-768.

[14]Luo, Y., Chen, X., Han, R., O′Donnell, M.A., 2001. Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2b demonstrates enhanced immunogenicity. Clin. Exp. Immunol., 123(2):264-270.

[15]Luo, Y., Yamada, H., Chen, X., Ryan, A.A., Evanoff, D.P., Triccas, J.A., O′Donnell, M.A., 2004. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin. Exp. Immunol., 137(1):24-34.

[16]Malmström, P.U., Sylvester, R.J., Crawford, D.E., Friedrich, M., Krege, S., Rintala, E., Solsona, E., di Stasi, S.M., Witjes, J.A., 2009. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol., 56(2):247-256.

[17]Mohanty, N.K., Malhotra, V., Nayak, R.L., Arora, R.P., 2002. Combined low-dose intravesical immunotherapy (BCG+ interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother., 14(2):194-197.

[18]Morales, A., Eidinger, D., Bruce, A.W., 1976. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116(2):180-183.

[19]Moro, A., Perea, S.E., Pantoja, C., Santos, A., Araña, M.D., Serrano, M., 2001. IFNalpha 2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line. Oncol. Rep., 8(2):425-429.

[20]O′Donnell, M.A., Lilli, K., Leopold, C., 2004. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J. Urol., 172(3):888-893.

[21]Pfeffer, L.M., Dinarello, C.A., Herberman, R.B., Williams, B.R., Borden, E.C., Bordens, R., Walter, M.R., Nagabhushan, T.L., Trotta, P.P., Pestka, S., 1998. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res., 58(12):2489-2499.

[22]Ratliff, T.L., 1992. Role of the immune response in BCG for bladder cancer. Eur. Urol., 21(S2):17-21.

[23]Shahin, O., Thalmann, G.N., Rentsch, C., Mazzucchelli, L., Studer, U.E., 2003. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol., 169(1):96-100.

[24]Shelley, M.D., Mason, M.D., Kynaston, H., 2010. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat. Rev., 36(3):195-205.

[25]Shintani, Y., Sawada, Y., Inagaki, T., Kohjimoto, Y., Uekado, Y., Shinka, T., 2007. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Int. J. Urol., 14(2):140-146.

[26]Suttmann, H., Jacobsen, M., Reiss, K., Jocham, D., Bohle, A., Brandau, S., 2004. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J. Urol., 172(4):1490-1495.

[27]van der Meijden, A.P., Brausi, M., Zambon, V., Kirkels, W., de Balincourt, C., Sylvester, R., 2001. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J. Urol., 166(2):476-481.

[28]Varaldo, P.B., Leite, L.C., Dias, W.O., Miyaji, E.N., Torres, F.I., Gebara, V.C., Armôa, G.R., Campos, A.S., Matos, D.C., Winter, N., et al., 2004. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect. Immun., 72(6):3336-3343.

[29]Xu, Y., Liu, W., Shen, H., Yan, J., Qu, D., Wang, H., 2009. Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response. Clin. Vaccine Immunol., 16(8):1121-1126.

[30]Yalçinkaya, F., Kamis, L., Ozteke, O., Gunlusoy, B., Yigitbasi, O., Unal, S., 1998. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int. Urol. Nephrol., 30(1):41-44.

[31]Yamada, H., Matsumoto, S., Matsumoto, T., Yamada, T., Yamashita, U., 2000. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J. Urol., 164(2):526-531.

[32]Yu, D.S., Lee, C.F., Chang, S.Y., 2007. Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64. J. Urol., 177(2):738-742.

[33]Zella, D., Barabitskaja, O., Casareto, L., Romerio, F., Secchiero, P., Reitz, M.S.Jr., Gallo, R.C., Weichold, F.F., 1999. Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J. Immunol., 163(6):3169-3175.